About Hydrogel Drug Delivery Systems
Hydrogels have an extensive vary of biomedical functions different than drug transport such as manufacturing contact lenses, wound dressings, and tissue engineering. The mechanism of drug transport by means of the usage of hydrogel entails diffusion-based drug launch from the hydrogel mesh or pores crammed with water. This reservoir shipping machine ensures time-independent and regular drug release. Different hydrogel merchandise are administered through more than a few routes of administration such as peroral, rectal, ocular, and transdermal amongst others. The hydrogel structures have various therapeutic functions such as for treating inflammatory diseases, cardiac sickness & cancer, and diabetic foot ulcer amongst others.
|Unit||Value (USD Million)|
Clinical trials using hydrogel drug delivery system structures have proven promising results, motivating pharmaceutical corporations to make investments in such therapeutic strategies. According to a 2019 NCBI report, the hydrogel was once employed in 223 medical trials for medicinal or diagnostic purposes, aside from contact lens trials. In the 223 medical trials, the hydrogel coil used to be employed in eight of them, the bulk hydrogel in 166, and the patch hydrogel in 99. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hydrogel Drug Delivery Systems market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Ashland (United States), Bausch and Lomb (Canada), Johnson & Johnson (United States), Micropore Technologies (United Kingdom), Medtronic (Ireland), Neurelis, Inc., (United States), Ocular Therapeutix, Inc, (United States), ProLynx Inc., (United States), Pfizer, Inc., (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players that are part of study coverage.
AMA Research has segmented the market of Global Hydrogel Drug Delivery Systems market by , Application (Healthcare, Hygiene, Contact Lenses, Tissue Engineering and Others) and Region.
On the basis of geography, the market of Hydrogel Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Composition, the sub-segment i.e. Silicon Hydrogel will boost the Hydrogel Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Hydrogels, the sub-segment i.e. Synthetic Hydrogels will boost the Hydrogel Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Hydrogel Drug Delivery Systems Market Dynamics:
- Increased Investment and Expenditure in R&D Operation
- Rising Adoption of Hydrogel in Ocular Delivery
- Compatibility Issues with Some of the Medicines
- High Cost of Hydrogels
|Road Blocks / Challenges|
- Supply Chain Disruptions
- Increasing Approval of New Hydrogel-Based Products
|Gaps & Opportunities|
- Growing Investment and Funding By Leading Pharma Companies in R&D Activities In Search Of A New Drug, Delivery Systems, And Diagnostic
In 2020, Bausch + Lomb, a main international eye fitness commercial enterprise of Bausch Health Companies, has launched the Bausch + Lomb INFUSETM silicone hydrogel each day disposable contact lens. It is the first silicone hydrogel every day disposable with a fabric infused with science named ProBalance to enhance ocular floor homeostasis and alleviate signs of contact lens dryness, which influences about 1/2 of the forty five Mn lens customers in the U.S.
the U.S. Food and Drug Administration approved Plenity manufactured by Gelesis a biotechnology company for the treatment of obesity. Plenity is a non-systemic, oral formulation made up of super absorbent hydrogel which is used for weight management in adults. The capsule works by inducing a feeling of fullness so that individuals eat less and eventually aid in losing weight.
Key Target Audience
Hydrogen Drug Delivery System Providers, Government Regulations, Venture Capitalists and Others
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.